SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 1

Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders

Veysel TAHAN
Ryan D. HEATH
Courtney COCKERELL
Ravinder MANKOO
Jamal A. IBDAH
Pages
79–88
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A growing number of studies have investigated the use of a fecal microbiota transplant as a potential therapy for these disease states.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Typical human gut flora has been well characterized in previous studies and has been noted to have significant differences when compared with the typical microbiome of various disease states involving the gastrointestinal tract.
📊
Key Findings & Data:Such diseases include Clostridium difficile colitis, inflammatory bowel disease, functional bowel syndromes, and various states of liver disease.
💡
Conclusion & Impact:A growing number of studies have investigated the use of a fecal microbiota transplant as a potential therapy for these disease states.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Typical human gut flora has been well characterized in previous studies and has been noted to have significant differences when compared with the typical microbiome of various disease states involving the gastrointestinal tract. Such diseases include Clostridium difficile colitis, inflammatory bowel disease, functional bowel syndromes, and various states of liver disease. A growing number of studies have investigated the use of a fecal microbiota transplant as a potential therapy for these disease states.

🔖

Cite This Article

TAHAN, V., HEATH, R. D., COCKERELL, C., MANKOO, R., IBDAH, J. A. (2022). Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 1, 79–88. https://ajindex.com/articles/551535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Duncan SH, Louis P, Flint HJ. Cultivable bacterial diversity from the human colon. Lett Appl Microbiol 2007;44:343–50.
  2. Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, et al. Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods. Clin Infect Dis 2015;60:S77–84. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435–8.
  3. Abdul-Hai A, Abdallah A, Malnick SD. Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol 2015;7:1679–84.
  4. Jasmohan S Bajaj, Douglas M Heuman, Phillip B Hylemon, Arun J Sanyal, Melanie B White, Pamela Monteith, et al. The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications. J Hepatol 2014;60:940–947.
  5. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59–64.
  6. Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G, et al. Gut microbiome of the Hadza hunter-gatherers. Nat Commun 2014;5:3654. Ishikawa E, Matsuki T, Kubota H, Makino H, Sakai T, Oishi K, et al. Ethnic diversity of gut microbiota: species characterization of Bacteroides fragilis group and genus Bifidobacterium in healthy Belgian adults, and comparison with data from Japanese subjects. J Biosci Bioeng 2013;116:265–70.
  7. Nakayama J, Watanabe K, Jiang J, Matsuda K, Chao SH, Haryono P, et al. Diversity in gut bacterial community of school-age children in Asia. Sci Rep 2015;5:8397. Bäckhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011;58:44–52.
  8. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010;4:409–16.
  9. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43–50. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012;18:5–12.
  10. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313:398–408.
  11. Choi HH, Cho YS. Fecal Microbiota